Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals

Submitted by amarin on Thu, 02/09/2023 - 13:01
Letter Underscores the Change That is Being Led by Amarin’s New Board Highlights Sarissa’s Track Record of Value Destruction in the Healthcare Space Sarissa Continues to Mislead Shareholders by Distorting Facts and Promoting Misinformation DUBLIN, Ireland and BRIDGEWATER., N.J., Feb.

Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals

Submitted by amarin on Thu, 02/09/2023 - 13:00
Letter Underscores the Change That is Being Led by Amarin’s New Board Highlights Sarissa’s Track Record of Value Destruction in the Healthcare Space Sarissa Continues to Mislead Shareholders by Distorting Facts and Promoting Misinformation DUBLIN, Ireland and BRIDGEWATER., N.J., Feb.

Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts

Submitted by amarin on Mon, 02/06/2023 - 13:01
Company Files Investor Presentation and Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a

Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts

Submitted by amarin on Mon, 02/06/2023 - 13:00
Company Files Investor Presentation and Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a

Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership

Submitted by amarin on Thu, 02/02/2023 - 21:30
Significantly Refreshed Board Overseeing Successful Execution of Amarin’s Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa’s Slate in Every Critical Area Chairman Per Wold-Olsen Brings Critical Experience and Leadership Releases Additional Board Videos Available at

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Submitted by amarin on Tue, 01/31/2023 - 13:26
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Submitted by amarin on Tue, 01/31/2023 - 13:25
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Submitted by amarin on Fri, 01/27/2023 - 13:45
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Submitted by amarin on Fri, 01/27/2023 - 13:45
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent

Amarin to Present at SVB Securities Global Biopharma Conference

Submitted by amarin on Fri, 01/27/2023 - 13:00
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.